Yahoo Web Search

Sign In

Search results

  1. 397.70
    Add to watchlist
    -3.06 (-0.76%)
    At close: Thu. Apr 25, 2024 4:00 PM EDT · Nasdaq Real Time Price (USD) · Pre-Market Time
    Full chart
    • Open
      402.44
      High
      403.88
      Low
      393.00
    • Mkt Cap
      102.79B
      P/E (TTM)
      28.65
      Div & Yield
      N/A & N/A
    • Prev. Close
      400.76
      52 Wk. Low
      320.01
      52 Wk. High
      448.40

    More about VRTX

    What analysts are saying
    Morningstar Bearish Published April 11 · Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases.... Read more
    Top stories

    Related stocks

    More on Yahoo Finance

  2. www.marketbeat.com › instant-alerts › nasdaq-vrtxVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given ...

    11 hours ago · Vertex Pharmaceuticals ( NASDAQ:VRTX - Get Free Report) last issued its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%.

  3. www-ft-com.ezproxy.cul.columbia.edu › content › 39edIts blockbuster cystic fibrosis treatment costs $300,000 a ...

    So effective is Vertex Pharmaceuticals’ blockbuster cystic fibrosis (CF) drug, Trikafta, that studies project it could extend the lives of some young patients by up to 45 years. As such, it is not cheap: in the US, it costs $300,000 per patient, ...

  4. Videos

    View all

  5. www.defenseworld.net › 2024/04/26 › vertexVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives ...

    11 hours ago · Vertex Pharmaceuticals stock opened at $397.70 on Friday. The stock has a 50-day simple moving average of $412.09 and a 200 day simple moving average of $398.37. The company has a quick ratio of 3 ...

  6. health.economictimes.indiatimes.com › news › pharmaRegeneron to collaborate on gene editing therapies with ...

    3 hours ago · Regeneron joins drugmakers Bayer and Vertex Pharmaceuticals in striking partnership deals with Mammoth for development of gene therapies. Mammoth, which was founded by Doudna, will receive $100 ...

  7. www.bizjournals.com › boston › newsSarepta CEO, Massachusetts’ highest paid CEO in 2022, sees ...

    11 hours ago · Reshma Kewalramani, the CEO of Vertex Pharmaceuticals, saw her total compensation cross the $20 million threshold last year. Across the river in Cambridge, Alnylam Pharmaceuticals Inc.

  8. www.physiciansweekly.com › exa-cel-eliminates-vasoExa-Cel Eliminates Vaso-Occlusive Crises in Most Sickle Cell ...

    11 hours ago · THURSDAY, April 25, 2024 (HealthDay News) — For almost all patients with sickle cell disease, treatment with exagamglogene autotemcel (exa-cel) eliminates vaso-occlusive crises, according to a study published in the April 24 issue of the New England Journal of Medicine. Haydar Frangoul, M.D., from the Sarah Cannon Research Institute at the ...

  9. People also ask

  10. markets.businessinsider.com › news › stocksMaintaining Hold on Neurocrine Amid Promising Yet Uncertain ...

    11 hours ago · Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and ACADIA Pharmaceuticals. According to TipRanks , Ear has an average return of 4.4% ...

  1. Searches related to Vertex Pharmaceuticals

    vertex pharmaceuticals stockregeneron pharmaceuticals
    vertex pharmaceuticals diabetes trialvertex
    vertex pharmaceuticals addressvertex game
    vertex pharmaceuticals careersvertex new york times
  2. People also search for